Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Anecova: First Babies Born in Poland with AneVivo Natural Fertilisation

Anecova
Posted on: 19 Sep 17

PR Newswire

LAUSANNE, Switzerland, September 19, 2017

LAUSANNE, Switzerland, September 19, 2017 /PRNewswire/ --

After starting the commercialisation of AneVivo, its first assisted reproductive technology device, Anecova is proud to announce a major breakthrough this summer: the birth of the 6 first babies ever conceived using AneVivo Natural Fertilisation treatment, at the GynCentrum's Polish facility in Katowice.

     (Logo: http://mma.prnewswire.com/media/462513/Anecova_Logo.jpg )

After several years of R&D and clinical development, Anecova has developed a more natural approach to assisted reproductive technology, AneVivo, a porous capsule device allowing bi-directional passage of fluids, nutrients, and other non-cellular components, to enable interaction between the embryos and the maternal environment. It allows fertilisation and very early embryo development directly within the maternal womb.

Martin Velasco, Founder, Chairman and CEO of Anecova, said: "We are very happy to announce the birth of the first babies using our AneVivo treatment at the Gyncentrum Katowice facilty, a clinic that has consistently demonstrated a very innovative and dynamic development over the past years. At Anecova, we are delighted to have now contributed to the birth of over 50 babies."

After these first six successful births, GynCentrum now offers AneVivo in 3 new and more natural treatments, thus demonstrating again its leadership in a more natural approach to assisted reproductive technology.

Dr. Dariusz Mercik, Medical Director of Gyncentrum Clinic, commented: "The AneVivo device allows fertilisation to happen in the mother's womb rather than in the laboratory. Fertilisation happens in a more natural environment, receiving nutrition and signals from the mother rather than from the culture media used in the laboratory. So far, the early results of this innovative procedure are very encouraging with a higher performance than traditional in vitro. The patients also highly appreciate having an active part in the fertilisation and very early development."  

"With the aim of coming even closer to natural conception, we are now offering AneVivo with three new treatments. Two of the new treatments, AneVivo Mild and AneVivo Natural Cycle require minimal and no stimulation. In combination with AneVivo, the fertilisation will not only happen in the maternal environment, but the physical impact for women will be minimized and the number of embryos used for a cycle limited."

"The third treatment, AneVivo with Egg Donation, will allow the recipient of the egg to play an active role from the start. Combined with AneVivo, the embryo fertilisation and its very early development will happen in the mother's womb."

About Anecova   
Anecova is a Swiss medical device company based at the EPFL Innovation Park in Lausanne. Anecova is working with world leading scientists and clinicians in the field of Assisted Reproductive Technology (ART) with the objective of developing more natural approaches to Assisted Reproductive Techniques (ART). The company is ISO certified (9001 and 13485). Its AneVivo device is European Certified (CE MARK) and has also received the approval of several regulators in Europe, including the HFEA in the UK. Anecova has been working in the past years in the development of a device allowing the fertilization and embryo development in the maternal environment instead of in a laboratory. AneVivo, Anecova's first commercialized device, allows clinics to offer Natural Fertilization treatments to their patients.

For more information go to http://www.anecova.com

Ab out Gyncentrum Fertility Clinic 
Gyncentrum proves cutting-edge treatments with the most advanced techniques of assisted reproductive treatment available on the market, including treatments with the newest method of classic In Vitro, which increases the probability of success, such as ICSI and IMSI. As one of the pioneer fertility clinics in Poland, Gyncentrum introduced PGD diagnosis, which can be used to test, identify and eliminate the risk of transmission of over 100 genetic conditions and diseases from parents to child.

The quality of a medical professional is reflected not only in career longevity but also by her/his acknowledgement by her/his peers as shown by certification, awards, commencements and consistent international collaboration. The numerous medical professionals who serve as part of the Gyncentrum Clinic in Poland embody this definition of quality. Additionally, Gyncentrum has established its reputation as a medical tourism specialist. Gyncentrum patients have also benefitted from the National Health Program: "Infertility Treatment Using In Vitro Fertilization for the years 2013-2016", which has helped thousands of patients undergo successful treatment.

For more information go to http://www.gyncentrum.pl

PR Newswire
www.prnewswire.com

Last updated on: 19/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.